Cardiff Oncology Inc Dossier - Source-backed chat

Cardiff Oncology Inc

CRDFNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.32

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.18Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $91.8M

Enterprise Value $83.2M

Shares Outstanding 68.7M diluted

Next Earnings Date29 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cardiff Oncology is a clinical-stage biotechnology company focused on developing onvansertib, a highly selective oral PLK1 inhibitor. The company recently reported outstanding Phase 2 (CRDF-004) data in first-line RAS-mutated metastatic colorectal cancer (mCRC), showing a 72.2% confirmed objective response rate (ORR) for the 30 mg onvansertib + FOLFIRI/bevacizumab arm compared to 43.2% for standard of care. While the clinical signal is highly compelling and has aligned FDA support for a Phase 3 registrational trial (CRDF-005), Cardiff faces significant near-term headwinds. The company's cash runway only extends into Q1 2027, meaning it must raise substantial capital to execute the expensive Phase 3 trial, which has triggered a going-concern warning in its SEC filings. Additionally, an active licensing dispute with Nerviano Medical Sciences over the rights to onvansertib introduces material legal risk. Consequently, a Hold recommendation is warranted until financing is secured and legal overhangs are resolved.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.00

Mean target$5.21

High · most bullish analyst$12.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5020%

The bear case materializes if the licensing dispute with Nerviano Medical Sciences escalates, leading to a termination of the onvansertib license or highly unfavorable court rulings that halt development. Alternatively, if Cardiff fails to raise capital to fund the Phase 3 trial, the company may be forced to suspend operations or undergo a highly dilutive restructuring under distressed conditions.

Base CaseCentral scenario

$2.0050%

The base case assumes Cardiff will successfully initiate the Phase 3 CRDF-005 trial but will experience significant dilution to fund it, given the current cash balance of $46.1 million and a quarterly burn rate of ~$12.3 million. The Nerviano dispute is expected to be settled out of court, likely resulting in increased royalty obligations or milestone payments that compress long-term margins. The stock is expected to trade sideways to slightly down as the market digests the impending dilution and legal overhang.

Bull CaseUpside scenario

$10.0030%

The bull case is driven by successful execution and funding of the Phase 3 CRDF-005 trial. If Cardiff secures a non-dilutive co-development partnership or raises capital on favorable terms, and subsequently resolves the Nerviano licensing dispute without losing onvansertib rights, the stock could re-rate dramatically. Onvansertib's potential to redefine first-line RAS-mutated mCRC (a massive underserved market with no specifically approved targeted therapies except for rare KRAS G12C mutations) represents a multi-billion dollar commercial opportunity.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Compelling Phase 2 efficacy data with a 72.2% confirmed ORR and a hazard ratio of 0.37/0.38 for PFS, demonstrating clear superiority over standard of care.
FDA alignment on the Phase 3 registrational trial design (CRDF-005), providing a clear regulatory pathway for both accelerated and full approval.
Strong newly appointed executive leadership team, including permanent CEO Mani Mohindru, CFO Josh Muntner, and COO Ajay Aggarwal, bringing deep clinical and capital markets expertise.

Key Investment Risks

Severe cash runway constraints, with current resources of $46.1 million only sufficient to fund operations into Q1 2027, creating an imminent need for highly dilutive financing.
Active legal dispute with licensor Nerviano Medical Sciences, which has alleged material breach of the onvansertib license agreement, threatening the company's core asset.
Substantial doubt about the company's ability to continue as a going concern, as formally disclosed in recent SEC filings.

Thesis Invalidation Triggers

Termination or loss of the onvansertib license agreement with Nerviano Medical Sciences.
Inability to secure financing or a strategic partner to fund the Phase 3 CRDF-005 trial before the end of 2026.
Any unexpected safety signals or failure to replicate Phase 2 efficacy in the Phase 3 trial.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.